Skip to content
Aminoscope
Head-to-head

NAD⁺ IV therapy vs NAD⁺ precursors

Same molecule, two delivery routes. One has randomized human data for raising NAD+; the other is a clinic infusion at $250 to $1,500 a session with no controlled outcome trial.

By Julian RothResearch & dataUpdated October 2026

Short answer

The evidence gap decides this one. NAD⁺ precursors have human clinical data behind them, while NAD⁺ IV therapy has only preclinical or minimal evidence, resting mostly on animal or lab work. NAD⁺ precursors raise blood NAD+ in human trials, but no human trial shows they extend healthspan, prevent disease or slow aging.

NAD⁺ IV therapy

Preclinical / minimal

No controlled outcome trial of IV NAD⁺ for any wellness use; the one human study found infused NAD⁺ is cleared from plasma quickly.

Full NAD⁺ IV therapy evidence review

NAD⁺ precursors

NR / NMN

Clinical data

Oral NR/NMN reliably raise blood NAD⁺ in RCTs — but whether that translates into anti-aging outcomes is still open.

Full NAD⁺ precursors evidence review

NAD⁺ IV therapy vs NAD⁺ precursors: head to head

FDA status / approved use

NAD⁺ IV therapy

Not FDA-approved; given as a clinic wellness service, usually compounded

NAD⁺ precursors

Marketed as longevity supplements
Marketed for

NAD⁺ IV therapy

Anti-aging, energy, addiction

NAD⁺ precursors

Cellular energy, anti-aging
Outcome areas

NAD⁺ IV therapy

Mitochondrial / cellular energy; Longevity / lifespan

NAD⁺ precursors

Mitochondrial / cellular energy; Longevity / lifespan
Evidence grade

NAD⁺ IV therapy

Preclinical / minimal

NAD⁺ precursors

Clinical data
How it works

NAD⁺ IV therapy

Essential coenzyme in cellular energy metabolism whose levels fall with age

NAD⁺ precursors

Precursors absorbed and converted into NAD+, a molecule that declines with age
Route and dosing

NAD⁺ IV therapy

IV infusion over 45 minutes to several hours, often on consecutive days

NAD⁺ precursors

Oral supplement
Headline human result

NAD⁺ IV therapy

Not established

NAD⁺ precursors

Raise blood NAD+ in human trials, but no human trial shows they extend healthspan, prevent disease or slow aging
Strongest evidence

NAD⁺ IV therapy

PK pilot, Front Aging Neurosci 2019. Little or no controlled human outcome data for the marketed useNAD⁺ IV therapy evidence reviewPubMed 31572171

NAD⁺ precursors

NR PK RCT, Nat Commun 2016NAD⁺ precursors evidence reviewPubMed 27721479
Key safety signal

NAD⁺ IV therapy

Moderate to severe gastrointestinal symptoms, raised heart rate and chest pressure during infusion

NAD⁺ precursors

Well tolerated in short-term trials; no long-term safety data
How it is obtained

NAD⁺ IV therapy

Administered in clinics; not an approved product

NAD⁺ precursors

Over the counter as a dietary supplement

marks a row where the two differ. “Not established” marks a cell the available evidence does not answer. Evidence grades come from our evidence matrix, which grades each molecule on the human data for the use it is marketed for.

Clinical data:
Tested in humans — but investigational, discontinued, or proven only on a surrogate marker (not the marketed outcome).
Preclinical / minimal:
Evidence is largely animal, in-vitro, or anecdotal. Little or no controlled human outcome data for the marketed use.

Our verdict

On evidence this is not close. Oral NR and NMN reliably raise blood NAD+ in randomized trials, while intravenous NAD+ has no controlled trial showing the anti-aging, energy or addiction benefits clinics sell it for; the one human IV study measured metabolism and found infused NAD+ is cleared from plasma quickly, and the addiction claims rest on uncontrolled case series. IV NAD+ is also not FDA-approved for any condition and is typically compounded, which adds purity and sterility variability. Neither route has been shown to extend healthspan, and the two have never been compared directly.

NAD⁺ IV therapy fits if

Realistically almost nobody on the evidence; the drip only makes sense for someone who has already accepted they are paying for a clinic service rather than a demonstrated benefit.

NAD⁺ precursors fits if

Anyone whose actual goal is raising NAD+, where oral NR or NMN costs a fraction of a session, needs no clinic visit, and has the randomized human data behind it.

NAD⁺ IV therapy vs NAD⁺ precursors: common questions

Is either NAD⁺ IV therapy or NAD⁺ precursors FDA-approved?
No. NAD⁺ IV therapy is not FDA-approved; given as a clinic wellness service, usually compounded. NAD⁺ precursors are marketed as longevity supplements.
Which has stronger human evidence, NAD⁺ IV therapy or NAD⁺ precursors?
NAD⁺ precursors. They have human clinical data (key source: NR PK RCT, Nat Commun 2016), while NAD⁺ IV therapy has only preclinical or minimal evidence (key source: PK pilot, Front Aging Neurosci 2019).
What are the main safety concerns with NAD⁺ IV therapy and NAD⁺ precursors?
For NAD⁺ IV therapy, watch for moderate to severe gastrointestinal symptoms, raised heart rate and chest pressure during infusion. NAD⁺ precursors are well tolerated in short-term trials; no long-term safety data.

Key studies behind each

NAD⁺ IV therapy

  1. Grant R, Berg J, Mestayer R, et al. (2019). A Pilot Study Investigating Changes in the Human Plasma and Urine NAD+ Metabolome During a 6 Hour Intravenous Infusion of NAD+. Front Aging Neurosci. PubMed 31572171
  2. Airhart SE, Shireman LM, Risler LJ, et al. (2017). An open-label, non-randomized study of the pharmacokinetics of the nutritional supplement nicotinamide riboside (NR) and its effects on blood NAD+ levels in healthy volunteers. PLoS One. PubMed 29211728
  3. Brakedal B, Dölle C, Riemer F, et al. (2022). The NADPARK study: A randomized phase I trial of nicotinamide riboside supplementation in Parkinson's disease. Cell Metab. PubMed 35235774
  4. Reyna K, Heinzen G, Patel N, Ritter M. (2026). Intravenous infusion of nicotinamide adenine dinucleotide (NAD+) versus nicotinamide riboside (NR): a retrospective tolerability pilot study in a real-world setting. Front Aging. PubMed 41704678

NAD⁺ precursors

  1. Trammell SA, Schmidt MS, Weidemann BJ, et al. (2016). Nicotinamide riboside is uniquely and orally bioavailable in mice and humans. Nat Commun. PubMed 27721479
  2. Martens CR, Denman BA, Mazzo MR, et al. (2018). Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults. Nat Commun. PubMed 29599478
  3. Yoshino M, Yoshino J, Kayser BD, et al. (2021). Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women. Science. PubMed 33888596
  4. Liao B, Zhao Y, Wang D, et al. (2021). Nicotinamide mononucleotide supplementation enhances aerobic capacity in amateur runners: a randomized, double-blind study. J Int Soc Sports Nutr. PubMed 34238308

The full evidence reviews

Where to get it

Where to get NAD⁺ therapy

Telehealth services offering NAD⁺ as oral precursors, prescription injections, or clinic IV drips. Formats and pricing vary — confirm current NAD⁺ options with the provider.

Disclosure: Aminoscope is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. Partners are listed first; a commission never changes what we write about a provider. How we make money.

Compare all 222 NAD⁺ providers →

Provider reviews we publish: Garcia Weight Loss, Aesthetics & Hormone TherapyModern AgeNP2GOOptimized HealthRegenCenVitaStir

Related comparisons